Anti-Mouse CD370 (CLEC9A/DNGR-1) [Clone 1F6] — Purified in vivo PLATINUM™ Functional Grade

Anti-Mouse CD370 (CLEC9A/DNGR-1) [Clone 1F6] — Purified in vivo PLATINUM™ Functional Grade

Product No.: I-2020

- -
- -
Clone
1F6
Target
CD370
Formats AvailableView All
Product Type
Monoclonal Antibody
Alternate Names
CD370, DNGR-1, C-Type Lectin Domain Family 9 Member A
Isotype
Mouse IgG1
Applications
FC
,
IF
,
in vivo
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Mouse
Recommended Dilution Buffer
Immunogen
RBL-2H3 cells expressing mouse DNGR-1 fused to an HA epitope
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 0.5 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM<sup>TM</sup> antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC
WB
Additional Applications Reported In Literature ?
IF
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
This clone 1F6 monoclonal antibody recognizes a direct epitope on mouse DNGR1/CLEC9A for CD8+ dendritic cells, which can be exploited for tumor therapy, whilst also recognizing necrotic cells. This antibody can recognize both the short and long isoform of DNGR-1, which varies in a segment of the stalk region.
Background
CLEC9A antibody, 1F6, recognizes C-type lectin domain family 9 member A (CLEC9A), also known as CD370 and DNGR-1. CLEC9A is a type II transmembrane glycoprotein that belongs to the C-type lectin superfamily. In mice and humans, CLEC9A is expressed by CD8a+ conventional dendritic cells (cDCs) in mice1,2 and BDCA3+ DCs in humans3, which are specialized for the cross-presentation of exogenous antigens on MHC class I4. In mice, type I interferon (IFN)-secreting plasmacytoid DCs (pDCs) also express CLEC9A2. The ligand for CLEC9A is filamentous actin exposed on apoptotic cells5,6, and ligation of CLEC9A results in the cross-presentation and induction of CD8 T cell responses. CLEC9A is a target for vaccine enhancement, and antibodies targeting CLEC9A in vaccination studies lead to enhanced presentation by DCs, eliciting CD8 and CD4 T cell proliferation and strong humoral immunity. In addition, antigen targeting DCs via CLEC9A can enhance anti-tumor immunity12.
Antigen Distribution
CD370 (CLEC9A) in mice is expressed on CD8+ DCs and at low levels by plasmacytoid DCs
NCBI Gene Bank ID
Research Area
Immunology
.
Innate Immunity

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

The most common in vivo applications of clone 1F6 in mice are the identification, tracking, depletion, and functional analysis of CD8⁺ conventional dendritic cells (cDCs) through its specific binding to the mouse protein CLEC9A/DNGR-1/CD370.

Key in vivo applications include:

  • Tracking and isolation of CD8⁺ cDCs: 1F6 is widely used to label and study this dendritic cell subset within living animals for immunological profiling and functional assays.
  • Functional studies and depletion: The antibody may be utilized to modulate, deplete, or analyze the role of CLEC9A-expressing cells in various disease models, including infection, autoimmunity, and cancer.
  • Tumor immunotherapy research: Due to the central role of CD8⁺ cDCs in cross-presentation and anti-tumor immune responses, clone 1F6 is applied in experimental tumor therapy studies to investigate dendritic cell–mediated immune mechanisms.
  • Antigen targeting: The specificity for CLEC9A allows for targeted delivery of antigens or adjuvants to dendritic cells in vivo, informing vaccine development and the study of immune responses.

Clone 1F6 is prized for its ability to distinguish CD8⁺ dendritic cells in mice, making it a useful tool for a range of in vivo immunological experiments, particularly those focused on dendritic cell biology, cross-presentation, and immune modulation.

Several antibodies and proteins are commonly used with or alongside 1F6 in the literature, depending on the target protein or the context (e.g., amyloid-beta research, interleukin studies, or specific protein targets like neurocan). When 1F6 refers to the IL-36 alpha/IL-1F6 antibody, the following are frequently used:

  • IL-36 family antibodies: Antibodies against other IL-36 isoforms, such as IL-36 beta (IL-1F8) and IL-36 gamma (IL-1F9), are often used in parallel with IL-36 alpha/IL-1F6 antibodies to study specificity and regulation within the IL-36 cytokine subfamily.
  • Secondary antibodies: Detection protocols frequently employ secondary antibodies, such as HRP-conjugated anti-goat IgG (when primary is goat) or Goat anti-rabbit IgG (Alexa Fluor 488) (when primary is rabbit), for immunoblotting, immunohistochemistry (IHC), and immunofluorescence (IF).

For context where 1F6 denotes a different antigen (such as amyloid-beta or neurocan):

  • In amyloid-beta research, 4G8, 6E10, mOC98, and mOC23 are common antibodies used together for cross-comparison of binding and epitope specificity.
  • In neurocan research (mouse brain ECM), an anti-neurocan antibody (clone 1F6) might be used alongside markers of neural tissue or other ECM proteins for co-localization or comparative expression analysis.

Summary Table: Commonly Co-Used Antibodies with 1F6

1F6 Target ContextCommonly Used Antibodies/ProteinsPurpose/Details
IL-36 alpha/IL-1F6IL-36 beta, IL-36 gamma antibodiesDifferentiation within cytokine family
HRP-conjugated anti-IgG, Alexa Fluor conjugatesDetection/visualization in IHC, WB, IF
Amyloid-beta (other 1F6s)4G8, 6E10, mOC98, mOC23Epitope/conformation comparison
Neurocan (N-terminal 1F6)ECM, neural markersStructural/functional neuronal studies

If you have a specific disease area or protein application in mind, please clarify, as the 1F6 clone/epitope can refer to different antibodies depending on context. The IL-36 context is most common for citations using “1F6” regarding inflammatory cytokines.

I don't have specific information about "clone 1F6" citations in the provided search results. The search results contain general information about DNA cloning history, cloning techniques, and citation metrics in scientific literature, but they do not reference any specific clone designated as "1F6."

To provide you with accurate information about clone 1F6, I would need search results that specifically discuss this particular clone. Clone 1F6 could refer to:

  • A specific cell line or bacterial clone used in research
  • A monoclonal antibody clone
  • A plasmid clone from a genomic library
  • A mammalian cell clone

If you're looking for information about a specific clone 1F6 from a particular research context (such as immunology, molecular biology, or cell culture), please provide additional details about the research area or the original study where this clone was described. This would help in locating the relevant scientific literature and citations associated with that specific clone.

There is no direct information in the provided search results about the dosing regimens of clone 1F6 across different mouse models. None of the sources specifically mention clone 1F6 or its dosing schedules in vivo or in any experimental mouse strains. Most results address general principles of antibody dosing, examples with other clones, or unrelated pharmacological agents.

Essential context and supporting details:

  • The only mention of clone 1F6 is on a product page, which does not provide protocols, recommended doses, frequencies, or variations in usage across mouse strains or disease models.
  • General principles for antibody dosing in mice indicate that regimens may vary by clone, experimental goal, and mouse model, with factors including dose level, dosing interval, and treatment duration often adapted to maximize efficacy or minimize adverse immune responses. These principles apply broadly but do not include clone-specific recommendations.
  • For other antibodies, dosing regimens commonly range from single injections to repeated doses every few days or weekly, with adjustments for chronic or acute models and immune tolerance considerations.
  • Specialized mouse models may require altered schedules or additional control arms due to variable immune responses, pharmacokinetics, and pathology induction.

Additional Relevant Information:

  • If you need dosing information for clone 1F6, consult the primary literature, manufacturer protocols, or contact researchers experienced with this clone.
  • When exact regimens are unavailable, a pilot study with dose titration, control arms, and careful monitoring is standard practice for benchmarking suitable antibody doses and intervals in mice.

Summary Table (no regimen data for 1F6):

CloneDoseIntervalMouse ModelSource
1F6Not providedNot providedNot provided

If your query aims to compare 1F6 with known clones like anti-CD115 (AFS98) or anti-IIb glycoprotein (6A6), detailed, model-specific dosing recommendations are available for those clones in the literature and may serve as approximate references.

References & Citations

1. Murphy KM, et al. (2012) Blood. 119(25):6052–62
2. Ahmet F, et al. (2008) Blood. 112(8):3264-3273
3. Brown GD, et al. (2008) J Biol Chem. 283(24):16693-701
3. Bevan MJ, et al. (2000) J Exp Med. vol. 192 (pg. 1685-1696) 4. Feest C, et al. (2012) Immunity. 36(4):635–45
5. Kitsoulis S, et al. (2012) Immunity. 36(4):646–57
6. Huang Y, et al. (2011) PNAS. 108(6):2384–9
7. Chan CEZ, et al. (2017) 2:31
8. Joffre OP, et al. (2010) Eur J Immunol. 40(5):1255–65
10. Lahoud M., et al. (2015) Eur. J. Immunol. 45:854–864
11. Caminschi I., et al. (2011) J Immunol. 187(2):842-50
12. Reis e Sousa C., et al. (2008) J Clin Invest. 118(6):2098-110
Flow Cytometry
IF
in vivo Protocol
General Western Blot Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.